New combo therapy for schizophrenia shows promise in small real-world trial
NCT ID NCT05169268
First seen May 02, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study looked at how well a combination of two drugs—aripiprazole long-acting injection (Abilify Maintena) and brexpiprazole (Rexulti)—works for people with schizophrenia in real-life clinics. Six participants were followed for 6 months to track changes in symptoms like psychosis, anxiety, and depression, as well as side effects. The goal was to see if this combo is effective and tolerable outside of strict research settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANXIETY DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Queen Mary Hospital
Hong Kong, 000000, Hong Kong
Conditions
Explore the condition pages connected to this study.